Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $15.0 million.

  • Legend Biotech's Share-based Compensation fell 0.64% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.8 million, marking a year-over-year decrease of 4.65%. This contributed to the annual value of $34.3 million for FY2022, which is 70.34% up from last year.
  • Per Legend Biotech's latest filing, its Share-based Compensation stood at $15.0 million for Q3 2025, which was down 19.69% from $18.7 million recorded in Q2 2025.
  • Legend Biotech's 5-year Share-based Compensation high stood at $21.7 million for Q2 2024, and its period low was $2.3 million during Q1 2021.
  • Over the past 3 years, Legend Biotech's median Share-based Compensation value was $15.6 million (recorded in 2023), while the average stood at $15.6 million.
  • Per our database at Business Quant, Legend Biotech's Share-based Compensation soared by 573.64% in 2021 and then decreased by 14.74% in 2025.
  • Legend Biotech's Share-based Compensation (Quarterly) stood at $5.2 million in 2021, then surged by 72.56% to $9.0 million in 2022, then increased by 20.87% to $12.4 million in 2023, then climbed by 22.09% to $15.1 million in 2024, then fell by 0.64% to $15.0 million in 2025.
  • Its Share-based Compensation stands at $15.0 million for Q3 2025, versus $18.7 million for Q2 2025 and $15.9 million for Q1 2025.